CONCORD BIOTECH
|
CONCORD BIOTECH Last 5 Year Financial Ratios History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Operational & Financial Ratios | |||||
| Earnings Per Share (Rs) | 24.94 | 35.52 | 29.45 | 22.95 | 183.92 |
| CEPS(Rs) | 31.90 | 40.72 | 34.57 | 28.11 | 21.50 |
| DPS(Rs) | 7.55 | 10.70 | 8.75 | 6.83 | 51.20 |
| Book NAV/Share(Rs) | 192.81 | 173.27 | 145.93 | 123.31 | 1,159.94 |
| Tax Rate(%) | 24.78 | 24.85 | 25.32 | 25.44 | 26.35 |
| Margin Ratios | |||||
| Core EBITDA Margin(%) | 34.88 | 42.23 | 42.50 | 40.86 | 37.73 |
| EBIT Margin(%) | 32.75 | 41.30 | 40.88 | 38.89 | 33.56 |
| Pre Tax Margin(%) | 32.67 | 41.21 | 40.57 | 37.74 | 32.72 |
| PAT Margin (%) | 24.57 | 30.97 | 30.30 | 28.14 | 24.10 |
| Cash Profit Margin (%) | 31.63 | 35.50 | 35.57 | 34.47 | 30.99 |
| Performance Ratios | |||||
| ROA(%) | 12.15 | 19.90 | 19.17 | 15.92 | 12.43 |
| ROE(%) | 13.54 | 22.26 | 21.88 | 20.06 | 16.64 |
| ROCE(%) | 18.04 | 29.62 | 29.13 | 26.70 | 21.66 |
| Asset Turnover(x) | 0.49 | 0.64 | 0.63 | 0.57 | 0.52 |
| Sales/Fixed Asset(x) | 0.93 | 1.25 | 1.25 | 1.13 | 1.06 |
| Working Capital/Sales(x) | 0.98 | 1.26 | 1.35 | 1.59 | 2.52 |
| Efficiency Ratios | |||||
| Fixed Capital/Sales(x) | 1.07 | 0.80 | 0.80 | 0.89 | 0.94 |
| Receivable days | 169.86 | 132.49 | 111.87 | 108.22 | 102.99 |
| Inventory Days | 97.92 | 68.07 | 75.42 | 87.15 | 87.67 |
| Payable days | 159.68 | 123.94 | 149.88 | 179.16 | 144.10 |
| Valuation Parameters | |||||
| PER(x) | 40.73 | 47.19 | 51.68 | - | - |
| PCE(x) | 31.85 | 41.17 | 44.02 | - | - |
| Price/Book(x) | 5.27 | 9.67 | 10.43 | - | - |
| Yield(%) | 0.74 | 0.64 | 0.57 | - | - |
| EV/Net Sales(x) | 10.06 | 14.61 | 15.62 | - | -0.03 |
| EV/Core EBITDA(x) | 25.25 | 31.81 | 34.08 | - | -0.06 |
| EV/EBIT(x) | 30.72 | 35.38 | 38.20 | -0.01 | -0.08 |
| EV/CE(x) | 5.26 | 9.67 | 10.36 | - | -0.01 |
| M Cap / Sales | 10.07 | 14.61 | 15.66 | - | - |
| Growth Ratio | |||||
| Net Sales Growth(%) | -12.10 | 18.01 | 19.20 | 19.67 | 15.56 |
| Core EBITDA Growth(%) | -23.76 | 18.31 | 21.38 | 29.11 | -12.99 |
| EBIT Growth(%) | -30.29 | 19.21 | 25.30 | 36.18 | -22.35 |
| PAT Growth(%) | -30.25 | 20.62 | 28.33 | 37.25 | -25.53 |
| EPS Growth(%) | -29.80 | 20.62 | 28.33 | -87.52 | -25.51 |
| Financial Stability Ratios | |||||
| Total Debt/Equity(x) | - | - | - | 0.02 | 0.05 |
| Current Ratio(x) | 7.39 | 6.17 | 6.30 | 3.79 | 1.84 |
| Quick Ratio(x) | 5.46 | 4.87 | 4.84 | 2.69 | 1.27 |
| Interest Cover(x) | 419.57 | 475.76 | 130.57 | 33.85 | 39.72 |
| Total Debt/Mcap(x) | - | - | - | - | - |
Compare Financial Ratios of peers of CONCORD BIOTECH
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CONCORD BIOTECH | ₹13,188.0 Cr | -1.8% | 5.3% | -29.2% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹452,982.0 Cr | 0.9% | 5.6% | 14.1% | Stock Analytics | |
| DIVIS LABORATORIES | ₹179,361.0 Cr | 1.2% | 3.7% | -1.2% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹164,737.0 Cr | 4.4% | 10.3% | 42.1% | Stock Analytics | |
| CIPLA | ₹115,655.0 Cr | -1.7% | 3.1% | -4.2% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹112,573.0 Cr | 0.2% | 5.7% | 6% | Stock Analytics | |
CONCORD BIOTECH Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CONCORD BIOTECH | -1.8% |
5.3% |
-29.2% |
| SENSEX | -0.5% |
3% |
-8.5% |
You may also like the below Video Courses
